Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

There is increasing evidence of the efficacy of dose-dense therapy in the management of platinum-resistant/refractory ovarian cancer. We report our experience of extended weekly carboplatin and paclitaxel in this population group. Twenty patients with platinum-resistant/refractory ovarian cancer rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, R, Graham, J, Mitchell, H, Brooks, A, Blagden, S, Gabra, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653750/
https://www.ncbi.nlm.nih.gov/pubmed/19223898
http://dx.doi.org/10.1038/sj.bjc.6604914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653750/
https://www.ncbi.nlm.nih.gov/pubmed/19223898
http://dx.doi.org/10.1038/sj.bjc.6604914

Ejemplares similares